Today's Trend
Marker Therapeutics, Inc. (NASDAQ: MRKR) has benefited from a favorable HC Wainwright research update, helping explain the stock’s recent increase. The analyst maintained a Buy rating and raised several near- and medium-term earnings forecasts, although the company is still expected to remain unprofitable.
- HC Wainwright raised its FY2026 EPS forecast to -$0.63 from -$0.83 and its FY2027 estimate to -$0.89 from -$1.34, signaling expectations for narrower losses. The firm also lifted estimates for Q3 2026 and each quarter of 2027. Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR) and CSPC Pharmaceutical Group
- The analyst increased the FY2028 forecast to -$0.85 from -$1.02 and raised the Q1, Q2, Q3 and Q4 2027 estimates, supporting the view that Marker Therapeutics’ cost structure or development outlook could improve over the intermediate term.
- Despite the revisions, HC Wainwright still projects losses through the forecast period. The current full-year consensus remains approximately -$0.74 per share, underscoring Marker Therapeutics’ early-stage, high-risk biotechnology profile.
- Longer-term forecasts were mixed: FY2029 EPS was reduced to -$0.95 from -$0.75, while FY2030 EPS was cut sharply to -$1.02 from -$0.75. These reductions indicate that profitability remains uncertain and could temper the positive impact of the nearer-term estimate increases.
Overall, the immediate catalyst is the analyst’s improved outlook for 2026–2028 and continued Buy rating. However, MRKR remains a speculative stock because it has a small market capitalization, negative earnings and substantial longer-term forecast uncertainty.